Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
19 hedge funds and large institutions have $8.81M invested in Trillium Therapeutics Inc. in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
320% more capital invested
Capital invested by funds: $2.1M → $8.81M (+$6.71M)
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$1.05M |
| 2 |
Morgan Stanley
New York
|
+$271K |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$227K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$11.5K |
| 5 |
Jane Street
New York
|
+$10.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$704K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 4 |
VF
Virtu Financial
New York
|
-$7.73K |
| 5 |
Two Sigma Investments
New York
|
-$7K |
TRIL Hedge Fund Activity: Q4 2019 in Review
19 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2019, worth a combined $8.81M — up 320% from $2.1M a quarter earlier.
Fund positioning in TRIL was balanced in Q4 2019: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $1.05M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $704K sold.
- 19 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $8.81M of Trillium Therapeutics Inc. stock for Q4 2019, up 320% quarter-over-quarter.
- 5 funds opened new Trillium Therapeutics Inc. positions in Q4 2019 and 5 closed out, a net change of 0 holders.
- The largest Trillium Therapeutics Inc. buyer in Q4 2019 was Sio Capital Management, an estimated $1.05M added.
- The largest Trillium Therapeutics Inc. seller in Q4 2019 was Matrix Capital Management Company, an estimated $704K sold.
Based on aggregated 13F filings for Q4 2019.